[1] [1] JIANG T, XIA Y, LV J, et al. A novel protein encoded by circ-MAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling[J]. Mol Cancer, 2021, 20(1): 66.

[3] [3] YANG W J, ZHAO H P, YU Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer[J]. World J Gastroenterol, 2023, 29(16): 2452-2468.

[4] [4] ZHAO G, SONG D, WU J, et al. Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis[J]. Front Immunol, 2022, 13: 955091.

[5] [5] LIU Q, WU Y, QIN Y, et al. Broad and diverse mechanisms used by deubiquitinase family members in regulating the type I interferon signaling pathway during antiviral responses[J]. Sci Adv, 2018, 4(5): eaar2824.

[6] [6] SUN S C. Deubiquitylation and regulation of the immune response[J]. Nat Rev Immunol, 2008, 8(7): 501-511.

[7] [7] GUO Y, JIANG F, KONG L, et al. OTUD5 promotes innate antiviral and antitumor immunity through deubiquitinating and stabilizing STING[J]. Cell Mol Immunol, 2021, 18(8): 1945-1955.

[8] [8] ZHU D, XU R, HUANG X, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppressionviapreventing ER-associated degradation of immune checkpoint protein PD-L1[J]. Cell Death Differ, 2021, 28(6): 1773-1789.

[9] [9] QI Y, WANG M, JIANG Q. PABPC1-mRNA stability, protein translation and tumorigenesis[J]. Front Oncol, 2022, 12: 1025291.

[10] [10] LIU Z, LI J, DING Y, et al. USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer[J]. Oncogene, 2022, 41(18): 2555-2570.

[11] [11] WANG H N, AN J H, ZONG L. Advances in artificial intelligence for predicting complication risks post-laparoscopic radical gastrectomy for gastric cancer: a significant leap forward[J]. World J Gastroenterol, 2024, 30(43): 4669-4671.

[12] [12] DENG L, MENG T, CHEN L, et al. The role of ubiquitination in tumorigenesis and targeted drug discovery[J]. Signal Transduct Target Ther, 2020, 5(1): 11.

[13] [13] DEWSON G, EICHHORN P J A, KOMANDER D. Deubiquitinases in cancer[J]. Nat Rev Cancer, 2023, 23(12): 842-862.

[14] [14] YAU R G, DOERNER K, CASTELLANOS E R, et al. Assembly and function of heterotypic ubiquitin chains in cell-cycle and protein quality control[J]. Cell, 2017, 171(4): 918-933. e20.

[15] [15] SPANO D, CATARA G. Targeting the ubiquitin-proteasome system and recent advances in cancer therapy[J]. Cells, 2023, 13(1): 29.

[16] [16] REN J, YU P, LIU S, et al. Deubiquitylating enzymes in cancer and immunity[J]. Adv Sci (Weinh), 2023, 10(36): e2303807.

[17] [17] CLAGUE M J, COULSON J M, URB S. Cellular functions of the DUBs[J]. J Cell Sci, 2012, 125(Pt 2): 277-286.

[18] [18] DENG J, HOU G, FANG Z, et al. Distinct expression and prognostic value of OTU domain-containing proteins in nonsmall-cell lung cancer[J]. Oncol Lett, 2019, 18(5): 5417-5427.

[19] [19] YE D, WANG S, WANG X, et al. Overexpression of OTU domain-containing ubiquitin aldehyde-binding protein 1 exacerbates colorectal cancer malignancy by inhibiting protein degradation of -CateninviaUbiquitin-proteasome pathway[J]. Bioengineered, 2022, 13(4): 9106-9116.

[20] [20] LIU X, ZHANG X, PENG Z, et al. Deubiquitylase OTUD6B governs pVHL stability in an enzyme-independent manner and suppresses hepatocellular carcinoma metastasis[J]. Adv Sci (Weinh), 2020, 7(8): 1902040.